GOAL STATEMENT
The goal of this activity is for learners to be better able to improve clinicians’ ability to use immunotherapy and/or PARP inhibitors in patients with early-stage TNBC through a case-based educational exercise.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the[list][item]Clinical data associated with newer therapies used to treat patients with TNBC[/list]Have greater competence related to[list][item] Selecting optimal therapy for a patient with TNBC, based on clinical data and other patient- or tumor-specific factors[item]Managing adverse events associated with therapies for TNBC[/list]Demonstrate greater confidence in their ability to[list][item]Apply clinical data for TNBC therapies to practice optimizing patient outcomes[/list]
ACCREDITATION STATEMENT
[JALOGO] [MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.5 [italic]AMA PRA Category 1 Credits[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.